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INTRODUCTION 
Hot-Melt-Extrusion (HME) is a flexible process that uses 
high temperature and pressure conditions to pump raw 
materials such as an Active Pharmaceutical Ingredient 
(API) and a pharmaceutical grade polymer through a barrel. 
The material is conveyed and mixed using intermeshing co-
rotating twin-screws and then pushed through a die to form 
a well-shaped strand. Due to the high mixing degree 
provided by the twin-screws, the drug is transformed from 
crystalline to amorphous form. The use of twin-screw 
extruders is currently being implemented within continuous 
manufacturing platforms (Crowley, 2007). 
Moreover, HME processes have been widely studied in 
areas such as plastics, food industry and more recently, in 
the pharmaceutical industry. Main focus comprises the 
development of immediate and sustained release dosage 
forms and more recently, the enhancement of oral 
bioavailability of poorly water soluble drugs. 
In this study, amorphous solid dispersions of a BCS Class II 
drug, Albendazole (ABZ), were achieved by HME 
technique using different hydrophilic carriers. Previous 
amorphous solid dispersions of ABZ were performed by 
Torrado et al., (1996) and Leonardi et al., (2009) using the 
solvent evaporation method. By the application of a cutting 
edge technique such as HME that can be applied in a 
continuous and more efficient manner, we developed a new 
successful application to produce amorphous solid 
dispersions of ABZ. 
METHODOLOGY 
Preparation of amorphous solid dispersions 
Albendazole (ABZ) (Sigma-Aldrich Company Ltd., 
Gillingham, Dorset, United Kingdom) and polymeric 
carriers such as Polyvinylpyrrolidone K12 (PVP K12 PF, 
BASF, Cheshire, United Kingdom) and Polyethylene glycol 
6000 (PEG 6000, Croda International, Yorkshire, United 
Kingdom) were used. 
Polymer was sieved to assure particle size homogeneity and 
then drug and polymer were blended using a Turbula® T2F 
mixer (Glen Mills Inc., New Jersey, United States). 
 
A Thermo Scientific® Process 11 co-rotating twin-screw 
extruder (40L/D) (Karlsruhe, Germany) with a 2mm 
diameter die was used to produce the extruded materials. 
Formulations comprising ABZ and polymer content of 
1/99, 5/95, 10/90 and 20/80 % (w/w) were produced using 
different processing conditions. Material strands were 
subsequently cooled at room temperature and stored in 
glass sealed containers for a total period of 6 months at 25 
and 50ºC. 
Characterisation techniques 
Miscibility studies 
The miscibility properties of ABZ with each of the 
polymeric carriers were assessed theoretically by applying 
Hansen solubility parameter calculations and experimental 
evidence was also shown by Hot-Stage Microscopy (HSM). 
Surface characterisation techniques 
A Hitachi SU 6600 high-resolution analytical FE-SEM 
(New York, United States) and a Bruker high-resolution X-
ray Micro-CT SkyScan 1272 (Kontich, Belgium) were used 
to provide information regarding material properties such as 
porosity, homogeneity and drug content uniformity within 
the extruded materials. 
Evaluation of amorphous behaviour 
The physicochemical properties of the extruded materials 
were characterised using a Bruker AXS D8 advanced 
transmission diffractometer (Karlsruhe, Germany) and a 
Mettler Toledo DSC 822e (Greifensee, Switzerland) 
differential scanning calorimeter to evaluate the formation 
of amorphous solid dispersions. 
Dissolution profile studies 
Dissolution curves were obtained under non-sink conditions 
using the Sirius T3 measurement system (East Sussex, 
United Kingdom) and dispersions exhibited an increased 
dissolution rate compared to pure ABZ. Other main 
properties such as water content and API quantification 
were obtained by Karl-Fisher method and High-
Performance Liquid Chromatography (HPLC). 
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RESULTS 
Miscibility Studies 
The excellent miscibility properties of ABZ with each 
carrier were proven by Hansen solubility parameter 
calculations where values below 7MPa were obtained.  
Further assessment was performed by the application of 
HSM under different temperature conditions to establish the 
initial melting temperature in each system. 
Scanning Electron Microscopy (SEM) 
All extruded materials, physical mixtures (PM) and pure 
ABZ were characterised by SEM analysis where the 
amorphous state and also certain porosity degree were 
observed. 
Computed Tomography (Micro-CT) 
Homogeneity, content uniformity and porosity properties of 
the extruded materials can be successfully determined by 
Computed Tomography (Micro-CT) (Sinka, 2004). In our 
study, it was observed that the higher the drug content, the 
higher porosity degree achieved in the case of ABZ ± PVP 
K12 formulations (Figure 1). Further studies will be 
performed in order to decrease the porosity degree. 
 
Figure 1. Micro-CT image of ABZ ± PVP K12 extruded 
material at 1/99 % (w/w) 
X-Ray Powder Diffraction (XRPD) 
Extruded materials, PM drug-polymer and pure ABZ 
patterns showed absence of crystalline material and 
therefore confirmed the presence of amorphous ABZ 
(Figure 2). 
 
Figure 2. Diffractograms of (a) ABZ ± PVP K12 formulations 
at time zero and (b) ABZ ± PVP K12 at 10/90 % (w/w) after 6 
months storage 
 
Differential Scanning Calorimetry (DSC) 
DSC thermograms of the extruded materials, PM and pure 
ABZ supported the information provided by XRPD data, 
where amorphous solid dispersions were observed. 
Characteristic Tg events of the extruded materials were 
identified and extruded materials proved to be stable over 
time, as no endothermic peaks due to re-crystallisation 
events were shown. 
Dissolution profile studies 
Dissolution profiles of the extruded materials showed a 
great increase of drug released (%) over time compared to 
physical mixtures (PM) and ABZ alone. In the case of 
ABZ-PVP K12 formulations at 10/90 and 20/80 % (w/w), 
supersaturated dissolution profile curves were achieved. 
CONCLUSIONS 
Amorphous solid dispersions of ABZ in PVP K12 and PEG 
6000 were obtained by HME technique, in comparison to 
previous studies where classical methods were employed. 
Extruded materials showed a great increase in drug 
dissolution rate in comparison to pure ABZ and also 
stability studies showed promising results that may lead to 
further oral bioavailability studies. 
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